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Abstract
The present scientiﬁc opinion deals with the evaluation of the safety of di-calcium malate (DCM)
proposed as a novel food ingredient and as a source of calcium for use in foods for the general
population, food supplements, total diet replacement for weight control and food for special medical
purposes (FSMP), and with the bioavailability of calcium from this source. The structural formula of the
proposed complex is based on expert judgement and not supported by any analytical data. On the
basis of the available data, the Panel concluded that there was insufﬁcient scientiﬁc evidence of a
difference between the proposed novel food ingredient named as di-calcium malate (DCM) and calcium
malate already authorised as a source of calcium included in Annex II to Directive 2002/46/EC.
Accordingly, the Panel was unable to assess the safety of DCM as a novel food ingredient. On the basis
of the results provided, the Panel considered that DCM does not completely dissociate into calcium and
malic acid. The Panel concluded that when DCM dissociates, calcium would be available following
ingestion of DCM and the bioavailability would appear similar to values reported for other sources of
calcium already permitted. Furthermore, the Panel concluded that on the basis of the information
available it was not possible to calculate the exposure to DCM as a source of calcium to foods for the
general population, food supplements, total diet replacement for weight control and FSMP.
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Summary
The present scientiﬁc opinion deals with the evaluation of the safety of di-calcium malate (DCM)
proposed as a novel food ingredient and as a source of calcium for use in foods for the general
population, food supplements, total diet replacement for weight control and food for special medical
purposes (FSMP), and with the bioavailability of calcium from this source. The safety of calcium itself,
in terms of amounts that may be consumed, and the consideration of calcium as a nutrient are outside
the remit of this Panel.
The Panel noted that the structural formula of the proposed complex, as indicated in the dossier, is
based on expert judgement and not supported by any analytical evidence (e.g. X-ray crystallography).
Following a request for additional information, the applicant did not provide any further data in support
to the proposed structural formula of the proposed complex. The Panel noted that the applicant
proposed a different chemical structure for DCM compared to that provided in the initial dossier. The
Panel considered that the scientiﬁc evidence submitted by the applicant does not demonstrate the
difference between ‘dicalcium malate (DCM)’, which is subject of the application under evaluation
and ‘calcium malate’ which is already included in the Annex II to Directive 2002/46/EC as one of
the mineral substances which may be added to food supplements, following a scientiﬁc opinion by
(EFSA AFC Panel, 2006).
The applicant has proposed chemical and microbiological speciﬁcations for DCM and provided
results from ﬁve non-consecutive batches. The Panel noted that some parameters in the proposed
speciﬁcations were not commensurate with the structure proposed.
The maximum limits proposed for arsenic is higher than the values obtained in the ﬁve batches
analysed. Based on the analytical results provided by the applicant, lower levels of the maximum limit
for arsenic present as an impurity, should be considered in the proposed speciﬁcations. Furthermore,
the Panel noted that the currently proposed speciﬁcations indicate a minimum limit for calcium and
malic acid while no maximum limits are provided.
The applicant provided analytical data on particle size of ﬁve non-consecutive lots of DCM.
However, the Panel considered that the described vibratory sieve testing method with the smallest
sieve opening of 45 lm is not appropriate to determine nano-size particles. The Panel also noted that
an average of 81.58% of the tested material passed through the smallest 45 lm sieve.
The Panel noted that the applicant did not submit any information on proposed uses and use levels
for DCM in the initial application dossier. Further to a request for additional information, the applicant
has submitted data on the proposed use and use levels of DCM as a source of supplemental calcium in
foods using the FAIM template (version 1). However, the Panel noted that the use levels as indicated
by the applicant in the FAIM template did not clearly refer to the maximum use levels, typical use
levels or to the amount of calcium available from DCM. Despite a request for clariﬁcation, the applicant
did not provide a reply.
Furthermore, the Panel noted that no information was provided for the typical and maximum daily
dose of DCM and the resulting typical and maximum daily calcium intake which was intended to be
achieved by the proposed use of the source for food supplements, total diet replacement products for
weight control and for food for special medical purpose.
The Panel noted that, besides a bioavailability study conducted in human volunteers, an in vitro
absorption study of calcium from DCM and an acute toxicity study performed in rats, no further
biological and toxicological data on DCM were submitted by the applicant as part of the dossier. The
applicant provided a justiﬁcation for not complying with the Tier 1 requirements of the 2012 ANS
Panel ‘Guidance for submission for food additive evaluations’ by stating that, following oral ingestion,
DCM readily dissociated into calcium and malic acid. Both calcium and L-malic acid are natural
constituents of the diet and also of the body, for which extensive data on their biological effects exist.
Following EFSA’s request, the applicant submitted a study report designed to provide some
evidence to support that DCM, when placed into acidic solution like that found in the stomach,
dissociated into its individual components (calcium and malic acid). On the basis of the results
provided, the Panel considered that DCM does not completely dissociate into calcium and malic acid.
On the basis of the available data, the Panel concluded that there was insufﬁcient scientiﬁc
evidence of a difference between the proposed novel food ingredient named as DCM and calcium
malate already authorised as a source of calcium included in Annex II to Directive 2002/46/EC.
Accordingly, the Panel was unable to assess the safety of DCM as a novel food ingredient.
The Panel concluded that based on the data provided DCM does not completely dissociate into
calcium and malic acid.
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The Panel concluded that when DCM dissociates, calcium would be available following ingestion of
DCM and the bioavailability would appear similar to values reported for other sources of calcium
already permitted.
Furthermore, the Panel concluded that on the basis of the information available it was not possible
to calculate the exposure to DCM as a source of calcium to foods for the general population, food
supplements, total diet replacement for weight control and FSMP.
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1. Introduction
The present scientiﬁc opinion deals with the evaluation of the safety of di-calcium malate (DCM)
proposed as a novel food ingredient and as a source of calcium for use in foods for the general population,
food supplements, total diet replacement for weight control and food for special medical purposes (FSMP),
and with the bioavailability of calcium from this source. The safety of calcium itself, in terms of amounts
that may be consumed, and the consideration of calcium as a nutrient are outside the remit of this Panel.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The European Union legislation lists nutritional substances that may be used for nutritional
purposes in certain categories of foods as sources of certain nutrients.
The relevant Union legislative measures are:
• Regulation (EC) No 258/97 of the European Parliament and the Council concerning novel foods
and novel food ingredients1;
• Directive 2002/46/EC of the European Parliament and of the Council on the approximation of
the laws of the Members States relating to food supplements2;
• Regulation (EC) 1925/2006 on the addition of vitamins and mineral and of certain other
substances to food3;
• Regulation (EU) No 609/2013 of the European Parliament and of the Council on the food
intended for infants and young children, food for special medical purposes, and total diet
replacement for weight control.4
The dossier relating to DCM as a source of calcium has been submitted to the Food Safety
Authority of Ireland (FSAI), the competent authority for novel food in Ireland, for an initial assessment
under Article 6(2) of Regulation (EC) No 258/97 concerning novel foods and novel food ingredients.
The applicant has asked the authorisation for DCM as a source of calcium in the following food
categories: foods for the general population (fortiﬁed food), food supplements, total diet replacement
for weight control and food for special medical purposes.
On 23 October 2015, FSAI forwarded to the Commission the initial assessment report, concluding
that an additional assessment by the European Food Safety Authority is required in line with Article 6
(3) of that Regulation (EC) No 258/97.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20025, the European Commission
asks the European Food Safety Authority to provide a scientiﬁc opinion:
• By carrying out the additional assessment for DCM as a novel food ingredient in the context of
Regulation (EC) No 258/97, and
• Following the outcome of the novel food assessment by evaluating the safety of DCM when
added for nutritional purposes to food supplements as a source of calcium to foods for the
general population, food supplements, total diet replacement for weight control and food for
special medical purposes, and the bioavailability of calcium from this source, in the context of
Regulation (EC) No 1925/2006, Directive 2002/46/EC and Regulation (EU) No 609/2013.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.
3 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and of certain other substances to foods. OJ L 183, 12.7.2002, p. 51.
4 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009.
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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1.1.3. Information on existing evaluations and authorisations
The Panel noted that the applicant provided information on the regulatory status of calcium and
malic acid.
Calcium
In 2007, the EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact
with Food (AFC) evaluated calcium citrate malate as a source for calcium added to foods for Particular
Nutritional Uses, food supplements and foods intended for the general population (EFSA AFC Panel,
2007). The AFC Panel concluded that the use of calcium citrate malate as source for calcium intended
for use in foods for Particular Nutritional Uses (PARNUTS) and foods for the general population
(including food supplements) is of no safety concern at the maximum levels estimated in this opinion.
Based on a potential exposure from all these sources (PARNUTS), food supplements and foods
intended for the general population, matching the tolerable upper intake level for calcium of 2,500 mg
calcium/day (SCF 2003), the equivalent exposure to citric acid would be around 1,400 mg/day and the
malic acid exposure would be around 500 mg/day.
In 2006, the AFC Panel evaluated calcium malate added to PARNUTS, food supplements and foods
intended for the general population (EFSA AFC Panel, 2006). The AFC Panel concluded that the use of
malates as sources for calcium is of no safety concern. However, it was stressed that for infants and
young children, only L-malates should be used. The Panel concluded that the bioavailability of calcium
malate is expected to be similar to the bioavailability from other dissociable calcium salts permitted to
be used for food supplements.
Calcium malate is included in Annex II of Directive 2002/46/EC on vitamin and mineral substances
which may be used in the manufacture of food supplements following a scientiﬁc opinion by EFSA AFC
Panel (2006). Calcium malate is authorised as a food additive (E 352) in accordance with the
Regulation (EU) No 1129/20116 amending Annex II to Regulation (EC) No 1333/20087 by establishing
a Union list of food additives and may be added to foods following the quantum satis principle.
Furthermore, calcium malate, calcium citrate malate and calcium hydroxide are allowed to be used
as food supplements in the EU as a source of calcium for dietetic foods (Regulation (EC) No 953/20098
on substances that may be added for speciﬁc nutritional purposes in foods for particular nutritional
uses and for food supplements and fortiﬁed foods (Regulation (EC) No 1170/20099 of 30 November
2009 as regards the lists of vitamin and minerals and their forms that can be added to foods, including
food supplements.
Calcium hydroxide is authorised as a food additive (E 526) in accordance with Annex II to
Regulation (EC) No 1333/2008 by establishing a Union list of food additives for the pH adjustment of
processed cereal based foods and baby foods and dietary foods for infants for special medical
purposes and special formulae for infants at the quantum satis level.
Malic acid
Malic acid and sodium-, sodium hydrogen-, potassium-, calcium- and calcium hydrogen-malate
(E 296, E 350–352) are authorised food additives in the European Union (EU) according to Annex II
and Annex III to Regulation (EC) No 1333/2008 on food additives. Currently, their re-evaluation as
food additives is still ongoing as foreseen in Regulation (EC) No 257/201010.
DL-Malic acid was ﬁrst evaluated by the Joint FAO/WHO Expert Committee on Food Additives
(JECFA) for use as an acidity regulator and ﬂavouring agent at its 9th meeting in 1965 at which point
the Committee did not specify an acceptable daily intake (ADI) level for the L-isomer given its well-
established pathway of metabolism and daily consumption of malic acid-containing foods (JECFA,
1967). Conversely, since only limited data were available on the metabolic fate of the D-isomer, the
6 Commission Regulation (EU) No 1129/2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament
and of the Council by establishing a Union list of food additives. OJ L 295, 21.11.2013, p. 1–212.
7 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 1–16.
8 Commission Regulation (EC) No 953/2009 on substances that may be added for speciﬁc nutritional purposes in foods for
particular nutritional uses. OJ L 269, 14.10.2009, p. 1-11. (No longer in force, date of end of validity: 19/7/2015, replaced by
Regulation (EU) No 609/2013).
9 Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European Parliament
and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards the lists of
vitamin and minerals and their forms that can be added to foods, including food supplements. OJ L 314, 1.12.2009, 1–7.
10 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00598
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Committee set a conditional ADI of 100 mg/kg body weight/day and requested further data on the
metabolism of D-malic acid in humans (JECFA, 1967). Furthermore, it was speciﬁed that with the
exception of therapeutic purposes, neither DL-malic acid nor D-malic acid should be added to food
intended for very young infants. Subsequently, based on additional data reviewed by the Committee,
indicating that adults are capable of metabolising D-malic acid, the previously set conditional ADI for D-
malic acid was withdrawn; however, the restriction with respect to foods for very young infants was
maintained (JECFA, 1970). The L-form of malic acid was re-evaluated by the Committee in 1999 for
use as a ﬂavouring agent (JECFA, 2000). The Committee concluded that there was ‘no safety concern
at current levels of intake when (L-malic acid) used as a ﬂavouring agent’ (i.e. 16 and 158 mg/day in
Europe and the US, respectively).
JECFA has also evaluated the calcium, potassium, and sodium salts of malic acid (JECFA, 1980;
JECFA, 1986). Concluding that the salts of malic acid are freely ionisable, it was considered to be
appropriate to establish ADIs on the basis of data on the corresponding anion (i.e. DL-malate). Thus,
the previously set ADI of ‘not speciﬁed’ for DL-malic acid was extended to a group ADI for DL-malic acid
and its calcium, potassium and sodium salts.
2. Data and methodologies
2.1. Data
The present evaluation is based on the data on DCM provided by the applicant in a dossier submitted
in support of its application (‘Documentation provided to EFSA’ n. 1), an initial assessment performed by
FSAI (‘Documentation provided to EFSA’ n. 2), the comments raised by the Member States during the
assessment of DCM as a novel food ingredient (‘Documentation provided to EFSA’ n. 3).
Additional data were generated by the applicant upon request from the ANS Panel during the
assessment of the dossier (‘Documentation provided to EFSA’ n. 4). The request for additional data
was discussed at a technical hearing held during a meeting of the Standing Working Group on
Applications on 29 January 201811 (‘Documentation provided to EFSA’ n. 5).
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009) and following the relevant
existing Guidances from the EFSA Scientiﬁc Committee.
The ANS Panel assessed the safety of DCM as a novel food ingredient in line with the principles laid
down in Commission Recommendation 97/618/EC.12 In particular, where it is stated that ‘Most of the
deﬁned chemical substances can probably be tested for their safety similarly to food additives by
utilising conventional methods of safety evaluation as described in the SCF Report No 10.’, the
Panel considered that to reﬂect state of the art scientiﬁc knowledge and welfare considerations the
reference to SCF Report No. 10 should be replaced by the latest existing guidance on the safety
evaluation of food additives, namely the Guidance for submission for food additive evaluations in 2012
(EFSA ANS Panel, 2012).
With respect to the evaluation of bioavailability of the nutrient (calcium) from the source DCM, the
principles contained in the ‘Guidance on submissions for safety evaluation of nutrients or of other
ingredients proposed for use in the manufacture of foods’ (SCF, 2001) were followed.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
In the original application dossier, a DCM complex, dicalcium malate chelate with a molecular
formula C8H8O10Ca2 was proposed (‘Documentation provided to EFSA’ n. 1).
11 https://www.efsa.europa.eu/sites/default/ﬁles/wgs/food-ingredients-and-packaging/applicationswg.pdf
12 Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary
to support applications for the placing on the market of novel foods and novel food ingredients and the preparation of initial
assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council. OJ L 253, 16.9.1997,
p. 1–36.
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Further to a request for additional clariﬁcation by EFSA on the substance under evaluation, the
applicant did not provide any additional data in support to the proposed structural formula of the
proposed complex, however, submitted an amendment to the dossier with respect to the identity of
the substance (‘Documentation provided to EFSA’ n. 5). According to the applicant, DCM is a salt made
of two calcium, one malic acid and two hydroxyl ions, C4H6Ca2O7 as molecular formula, a molecular
weight of 246.25 g/mol and CAS number 671197-49-2. The chemical structure as provided by the
applicant is presented in Figure 1. The applicant stated that DCM is different from calcium malate (CAS
17482-42-7).
The Panel noted that the identity of the substance named DCM proposed in the original application
dossier (dicalcium malate chelate (C8H8O10Ca2) (‘Documentation provided to EFSA’ n. 1) is different
from DCM proposed in the amended dossier (dicalcium malate (C4H6O7Ca2) (‘Documentation provided
to EFSA’ n. 5) and the Panel considered the latter as representing the substance under evaluation.
According to the applicant, the calcium content can be analysed via inductively coupled plasma
(ICP) spectrometry and the quantity of malic acid in the product analysed via high-performance liquid
chromatography (HPLC) analysis. The quantity of water in the product was calculated via moisture
balance. The applicant compared the Fourier-transform infrared (FTIR) spectrum of DCM with the one
from calcium hydroxide and DL-malic acid; a broad signal from 3,600 to 3,000 cm1 is observed
instead of the sharp peak at approximately 3,450 cm1 for DL-malic acid; this shows coordination
between carboxylate and the metal but the FTIR spectrum does not permit to reach any conclusion on
the structure of DCM. No comparison with the FTIR spectrum for calcium malate (CAS 17482-42-7)
was submitted to demonstrate that DCM is different from the already authorised calcium malate.
According to the information provided by the applicant (‘Documentation provided to EFSA’ n. 5),
DCM is identiﬁed as follows:
Chemical name: Di-calcium malate
Description: White to off-white, ﬁne powder, with no or a slight scent
Solubility: Very slightly soluble in water; solubility increases in the
presence of hydrochloric acid.
Average composition of
each component:
Calcium: ≥ 29% (32.5–29.1%)
Malic acid: 64% (56.6–53.0%)
Moisture: ≤ 6% (2.95–0.84%)
The applicant provided analytical data on particle size distribution of ﬁve lots of DCM
(‘Documentation provided to EFSA’ n. 4) tested using a vibratory sieve testing apparatus. The
Panel noted that the applicant provided a description of the method of analysis used for determining
the particle size distribution. The Panel also noted that the results were reported in three different
formats from the same data. The ﬁrst format is as a percentage of the total mass retained above or
on top of each sieve. The second is a cumulative percentage of the total mass retained above or on
top of each sieve as a progression through the sieve nest. Finally, the data are reported as a
percentage of the total mass that passed through each sieve. The data are summarised in Table 1.
Figure 1: Chemical structure for DCM as proposed by the applicant following a request for additional
information (‘Documentation provided to EFSA’ No. 5)
Table 1: Results of particle size distribution analysis of ﬁve batches of di-calcium malate (DCM)
US Sieve No.
Opening
(lm)
Percentage
above (%)
Cumulative above
(%)
Percentage
below (%)
Ave SD RSD Ave SD RSD Ave SD RSD
35 500 0.10 0.03 31 0.10 0.03 31 99.90 0.03 0
45 355 0.29 0.20 69 0.39 0.22 57 99.61 0.22 0
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On the basis of the data provided by the applicant, the Panel considered that the described
vibratory sieve testing method with the smallest sieve opening of 45 lm is not appropriate to
determine nano-size particles. The Panel also noted that an average of 81% of the tested material
passed through the smallest 45 lm sieve.
The Panel considered that the scientiﬁc evidence submitted by the applicant (initial application
dossier and additional data provided) does not demonstrate the difference between ‘dicalcium malate
(DCM)’, which is subject of the application under evaluation and ‘calcium malate’ which is already
included in the Annex II to Directive 2002/46/EC as one of the mineral substances which may be
added to food supplements, following a scientiﬁc opinion by EFSA AFC Panel (2006).
3.1.2. Speciﬁcations
The speciﬁcations for DCM as proposed by the applicant are listed in Table 2.
US Sieve No.
Opening
(lm)
Percentage
above (%)
Cumulative above
(%)
Percentage
below (%)
Ave SD RSD Ave SD RSD Ave SD RSD
60 250 0.45 0.15 33 0.84 0.32 38 99.16 0.32 0
80 180 0.74 0.10 13 1.58 0.35 22 98.42 0.35 0
120 125 1.20 0.16 13 2.78 0.20 7 97.22 0.20 0
170 90 1.67 0.22 13 4.45 0.09 2 95.55 0.09 0
230 63 4.25 1.78 42 8.70 1.83 21 91.30 1.83 2
325 45 9.72 3.09 32 18.42 4.29 23 81.58 4.29 5
Pan N/A 81.58 4.29 5 100.00 0.00 0 0.00 0.00 N/A
Ave: average; SD: standard deviation; RSD: residual standard deviation; N/A: not applicable.
Table 2: Speciﬁcation for DCM as proposed by the applicant
Speciﬁcation parameters Speciﬁcation value Analytical method
Description A white to off-white, ﬁne powder,
with no or slight scent
Visual and olfactory inspection
Identiﬁcation
Dicalcium malate Passes test FTIR analysis
Calcium Passes test Flame test for calcium
Assay
Assay NLT 88% Potentiometric titration
Calcium content NLT 29% ICP-AES
Malic acid content 440–600 mg/g HPLC
pH 11.5–12.5 (in water) pH meter
Moisture/loss of drying NMT 6.0% Moisture balance
Fluoride NMT 30 ppm Ion-speciﬁc electrode
Fumaric acid NMT 1.0% HPLC
Maleic acid NMT 0.05% HPLC
Magnesium and alkali salts NMT 4.8% ICP-AES
Heavy metals
Arsenic NMT 3.0 ppm ICP-AES
Lead NMT 0.5 ppm ICP-AES
Cadmium NMT 0.5 ppm ICP-AES
Mercury NMT 0.1 ppm ICP-AES
Microbiological speciﬁcations
Total plate count Less than 10,000 FDA BAM 8th Edition
Mould and yeast Less than 1,000 FDA BAM 8th Edition
Coliform count Less than 10(a) FDA BAM 8th Edition
Salmonella Negative FDA BAM 8th Edition
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The Panel noted that the assay as proposed in the speciﬁcations relies exclusively on the analysis of
calcium in the ﬁnal product DCM. Additionally, the minimum amount proposed for malic acid (440 mg/g)
would correspond to 26% of Ca that it less than the 29% proposed in the same speciﬁcations.
Furthermore, the Panel noted that the applicant proposed limits for magnesium without justifying its
presence in DCM.
The results of ﬁve non-consecutive batches analyses on DCM indicated that it is a consistent
product compliant with some of the parameters of the proposed speciﬁcations, including those
established for microbiological and heavy metals contaminations.
The maximum limits proposed for arsenic is higher than the values obtained in the ﬁve batches
analysed (< 1 ppm). Based on the analytical results provided by the applicant, lower levels of the
maximum limit for arsenic present as impurity, should be considered in the proposed speciﬁcations.
Furthermore, the Panel noted that the currently proposed speciﬁcations indicate a minimum limit
for calcium and malic acid whilst no maximum limits are provided.
3.1.3. Manufacturing process
The Panel noted that the information on manufacturing process provided by the applicant in the
dossier (‘Documentation provided to EFSA’ n. 1) is claimed as conﬁdential.
According to the applicant, DCM is manufactured from DL-malic acid (FCC grade) and calcium
hydroxide (FCC grade) under aqueous conditions in accordance with current Good Manufacturing
Practices (GMP) and with the Hazard Analysis Critical Control Point (HACCP) system.
All the speciﬁcation data sheets for the raw materials were provided by the applicant.
The Panel considered that the method outlined by the applicant sufﬁciently described the
manufacturing process for a calcium malate, however, it does not demonstrate the speciﬁc production
of DCM.
3.1.4. Methods of analysis in food
According to the applicant the amount of calcium may be determined by the inductively coupled
plasma atomic emission spectroscopy (ICP-AES) method and expressed as the level of DCM added to
foodstuff; each milligram of calcium assayed is equivalent to 3.45 mg of DCM minimum. The
Panel noted that the ICP-AES method determines the content of total calcium in the foodstuff and is
not speciﬁc only for calcium from DCM.
3.1.5. Stability of the substance, and reaction and fate in food
According to the applicant, in the event of degradation of DCM, the expected degradation products
would be calcium ions, hydroxide ions (OH-) and malic acid.
Six random lots of DCM were selected for stability testing. Products were tested at the time of
release for calcium content and pH (‘Documentation provided to EFSA’ n. 1). The product was stored
for 3 years in a polystyrene container at ambient temperature and controlled humidity. At the end of
3 years, the samples were tested again for calcium content and pH. Differences between initial and
ﬁnal results were calculated and evaluated, taking into account expected analytical variation. According
to the applicant, the pH results would indicate that there is chemical stability, but there is a signiﬁcant
reduction of calcium content over 3 years. According to the applicant, evaluation of the data did not
indicate any outliers that were causing bias of the data. Further evaluation of the physical speciﬁcation
yielded some insight. This product had a signiﬁcant moisture gain over 3 years – 28% from initial
values. The Panel noted that the moisture is calculated theoretically by ‘moisture balance’
(Section 3.1.2), and therefore, the explanation given by the applicant would not explain the loss of
calcium content observed.
No stability studies for DCM in a food matrix were submitted in the dossier.
Speciﬁcation parameters Speciﬁcation value Analytical method
Escherichia coli Less than 10(a) FDA BAM 8th Edition
Staphylococcus aureus Less than 10(a) FDA BAM 8th Edition
FTIR: Fourier-transforming infrared; NLT: not less than; ICP-AES: inductively coupled plasma atomic emission spectroscopy;
HPLC: high-performance liquid chromatography; NMT: not more than; CFU: colony forming units; BAM: bacteriological analytical
manual.
(a): Less than 10: detection limit for the test.
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3.2. Proposed uses and use levels
The Panel noted that the applicant did not submit any information on proposed uses and use levels
for DCM, in the initial application dossier (‘Documentation provided to EFSA’ n. 1).
Further to a request for additional information, the applicant has submitted data on the proposed
use and use levels of DCM as a source of supplemental calcium in foods using the FAIM template
(version 1) (‘Documentation provided to EFSA’ n. 4). However, the Panel noted that the use levels as
indicated by the applicant in the FAIM template did not clearly refer to the maximum use levels, typical
use levels or to the amount of calcium available from DCM. Despite a request for clariﬁcation, the
applicant did not provide any additional data.
Furthermore, the Panel noted that no information were provided for the typical and maximum daily
dose of DCM and the resulting typical and maximum daily calcium intake which was intended to be
achieved by the proposed use of the source for food supplements, total diet replacement products for
weight control and for FSMP (‘Documentation provided to EFSA’ n. 4).
3.3. Exposure data
The Panel noted that the applicant has provided an estimate of the exposure to DCM based on the
output obtained using the FAIM model (version 1) (‘Documentation provided to EFSA’ n. 4).
However, the Panel considered that the data provided did not allow a reliable estimate of the
exposure to DCM as a source of calcium to foods for the general population, food supplements, total
diet replacement for weight control and FSMP.
3.4. Biological and toxicological data
The Panel noted that, besides a bioavailability study conducted in human volunteers, an in vitro
absorption study of calcium from DCM and an acute toxicity study performed in rats, no further
biological and toxicological data on DCM were submitted by the applicant as part of the dossier.
The applicant provided a justiﬁcation for not complying with the Tier 1 requirements in the
‘Guidance for submission for food additive evaluations’ (EFSA ANS Panel, 2012) by stating that,
following oral ingestion, DCM readily dissociated into calcium and malic acid.
Both calcium and L-malic acid are natural constituents of the diet and also of the body, for which
extensive data on their biological effects exist.
3.4.1. Bioavailability of calcium from DCM
Data on dissociation of DCM
According to the applicant, DCM dissociates at low pH into calcium and malic acid and any DCM not
dissociated is assumed to be excreted in the faeces or metabolised by gut microﬂora. However, the
Panel noted that the applicant did not provide any analytical data in support of these assumptions
(‘Documentation provided to EFSA’ n. 1).
Following EFSA’s request, the applicant submitted a study report designed to provide some evidence
to support that DCM, when placed into acidic solution like that found in the stomach, dissociated into its
individual components (calcium and malic acid) (‘Documentation provided to EFSA’ n. 4).
A method using a calcium ion selective electrode (ISE) was modelled to measure the concentration
of calcium ions (Ca2+) in an environment similar to the human stomach.
A sample of DCM having the equivalent of 1,000 ppm (1 mg/L = 1 ppm) of calcium or calcium
hydroxide (Ca(OH)2) was added to 1 L of water heated to 37°C. The solution was titrated in 1 mL
portions using simulated gastric ﬂuid (0.1 M HCl; pH 1.2). The concentration of Ca2+ ions was
measured and recorded after each 1 mL added. A maximum of 50 mL simulated gastric ﬂuid (SE) was
added to the solution, and plotted using ml’s of acid vs ppm of Ca2+ ions. In addition, a pH electrode
was setup to capture the pH of the solution.
The results showed that unbound Ca2+ ranged from 600 to 900 ppm (60–90% dissociated) but
never completely dissociated at 1,000 ppm (100%). The results also show that maximum dissociation
occurred at pH 6, but never continues to increase higher as pH drops lower. According to the
applicant, this suggests that the ionic strength of the solution increases at lower pH causing the
calcium to bind to a surplus of anions present in solution.
On the basis of the results provided, the Panel considered that DCM does not completely dissociate
into calcium and malic acid.
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Human study
The bioavailability and tolerability of calcium from four calcium supplements (DCM, calcium amino
acid chelate (18%), calcium amino acid chelate (26%) and calcium carbonate) were investigated in a
double-blind, cross-over trial in 15 healthy volunteers (‘Documentation provided to EFSA’ n. 1),
performed in accordance with Good Clinical Practice (GCP) in 2007 (Documentation provided to EFSA
n. 1). Each subject received 900 mg of calcium from one of the four different formulations on four
separate occasions. Serum samples were taken at 0, 0.5, 2, 4, 6, 9 and 12 h post-treatment. The
Panel noted that with a such high level of calcium, intestinal calcium uptake may be saturated and
therefore differences in uptake between different preparations may not be evident.
In comparison to baseline levels, a statistically signiﬁcant increase in the concentration of serum
calcium was observed beginning 4 h after supplementation with DCM, persisting for the remainder of
the sampling period. A maximum calcium serum concentration (Cmax) of 2.44 mmol/L (vs 2.30 mmol/L
at baseline) was attained at 7.23 h following oral treatment with DCM. In comparison to baseline
calcium levels, ingestion of calcium amino acid chelate (18%) resulted in the greatest increase in the
concentration of serum calcium. Compared to supplementation with DCM or calcium amino acid
chelate (26%), a signiﬁcantly higher maximum serum calcium level was obtained within the shortest
period of time when subjects received calcium from calcium carbonate.
The greatest area under the curve (AUC) was observed with calcium amino acid chelate (18%);
however, no signiﬁcant differences were observed in the AUC measurements among any of the 4
calcium preparations. Generally, all four AUC values were relatively low (i.e. in the range of
27.34–28.86 mmolh/L) indicating that the bioavailability of calcium from all of these sources was
generally poor. According to the study authors, this may have been due to the elimination of absorbed
calcium during the ﬁrst-pass effect. The half-life (t1/2) for calcium from DCM was determined to be
42.28 h, which was signiﬁcantly longer than the t1/2 reported for calcium from calcium amino acid
chelate (26%) and calcium carbonate. Generally, calcium from calcium carbonate appeared to be
absorbed most efﬁciently; however, calcium from DCM exhibited the longest t1/2.
According to the applicant, the increase in calcium serum levels following ingestion of DCM
supports that the compound dissociates under physiological conditions, allowing for the subsequent
absorption of calcium, as well as malic acid. In the same manner as other similar salts, the undissolved
portion of DCM is expected to pass through the gastrointestinal tract, and will be excreted in the
faeces.
In Vitro Study – Absorption of calcium from DCM
The applicant provided results on an in vitro assay carried out to determine the solubility of DCM
under different pH conditions (‘Documentation provided to EFSA’ n. 1). A quantity of 5 g of DCM were
dissolved in 40 mL of water and the pH adjusted to different levels ranging from pH 2 to 7 by addition
of 6 M hydrochloric acid. The solubility of DCM was shown to be pH-dependent, such that at a pH of
7, 5.2% of DCM was dissolved, whereas at a pH of 2, solubility increased more than twofold to 12.6%.
At pH 4, the solubility of DCM was calculated to be 5.9%. According to the applicant, on the basis of
these results, DCM is expected to dissolve under the acidic conditions encountered in the stomach
upon ingestion. However, according to the applicant, calcium absorption does not occur in the
stomach, but instead calcium is absorbed predominantly from the small intestine. As free calcium ions
enter the small intestine, where the pH is approximately 6.5, the dissociated ions may at least in part
re-precipitate (Heaney et al., 1990). Moreover, according to the applicant, absorption of the ionised
calcium will also depend on other factors such as concomitant intake of foods that may increase or
decrease its absorption.
3.4.2. Acute toxicity
DCM from a single lot has been evaluated in an unpublished single-dose oral toxicity study
conducted in accordance with Good Laboratory Practice (GLP) in three healthy female Wistar albino
rats (Documentation provided to EFSA n. 1). No mortality was recorded at 5,000 mg/kg body weight.
4. Discussion
The current assessment by the Panel is based on the information submitted in the application
dossier (Documentation provided to EFSA n. 1) and the additional information provided by the
applicant in response to EFSA’s requests (Documentation provided to EFSA n. 4, 5).
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According to the applicant, DCM is a salt made of two calcium ions and one malic acid and it is
different from calcium malate (CAS 17482-42-7). Calcium malate is included in Annex II of Directive
2002/46/EC on vitamin and mineral substances which may be used in the manufacture of food
supplements following a scientiﬁc opinion by EFSA (EFSA AFC Panel, 2006).
The Panel noted that the manufacturing process described for DCM does not demonstrate that the
synthesis of DCM is different from that of calcium malate.
The Panel has requested scientiﬁc data to demonstrate that the substance under evaluation is
different from ‘calcium malate’, and the applicant was not able to provide any scientiﬁc evidence. In
the absence of these data, the Panel is unable to conclude that the substance presented as DCM
would be different from calcium malate already authorised as a nutrient source.
The applicant has proposed chemical and microbiological speciﬁcations for DCM and provided
results from ﬁve non-consecutive batches. The Panel noted that some parameters in the proposed
speciﬁcations were not commensurate with the structure proposed.
The Panel noted that in the stability report provided by the applicant, a signiﬁcant reduction in the
calcium content occurred after storage at room temperature for 3 years. The Panel noted that no
explanation for that decrease was provided by the applicant.
On the basis of the information provided by the applicant, the Panel was unable to calculate the
typical and maximum daily calcium intake resulting from the proposed uses of DCM as a source of
calcium intended to be added as a source of calcium to foods for the general population, food
supplements, total diet replacement for weight control and FSMP.
The Panel noted that the toxicological data set was limited to an acute oral toxicity study, an
in vitro study and a double-blind, cross-over trial performed in healthy human volunteers with limited
safety parameters.
According to the applicant, DCM dissociates into its main components (calcium and malic acid);
however, on the basis of the data available, the Panel concluded that DCM does not completely
dissociate into calcium and malic acid, consequently, Tier 1 toxicity studies would be needed to
evaluate the safety of DCM.
On the basis of the data submitted by the applicant, the Panel considered that calcium is
bioavailable from the source.
5. Conclusions
On the basis of the available data, the Panel concluded that there was insufﬁcient scientiﬁc
evidence of a difference between the proposed novel food ingredient named as DCM and calcium
malate already authorised as a source of calcium included in Annex II to Directive 2002/46/EC.
Accordingly, the Panel was unable to assess the safety of DCM as a novel food ingredient.
The Panel concluded that based on the data provided DCM does not completely dissociate into
calcium and malic acid.
The Panel concluded that when DCM dissociates, calcium would be available following ingestion of
DCM and the bioavailability would appear similar to values reported for other sources of calcium
already permitted.
Furthermore, the Panel concluded that on the basis of the information available it was not possible
to calculate the exposure to DCM as a source of calcium to foods for the general population, food
supplements, total diet replacement for weight control and FSMP.
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1) Dossier ‘Application for the approval of dicalcium malate as a source of calcium for use in the
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Submitted by Albion Laboratories, Inc.
2) Initial assessment of di-calcium malate (DCM) as a novel food ingredient. Food Safety
Authority Ireland (FSAI). March 2016.
3) Member States comments and objections. March 2016.
4) Additional information. January 2018. Submitted by Albion Laboratories, Inc. in response to a
request from EFSA.
5) Additional data provided as follow-up from technical hearing at ANS SWG on applications on
29 January 2018 as a web/teleconference. March 2018.
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Abbreviations
ADI acceptable daily intake
AFC EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with
Food
ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
AUC area under the curve
BAM bacteriological analytical manual
CAS Chemical Abstracts Service
CFU colony forming units
Cmax maximum concentration
DCM di-calcium malate
FCC Food Chemical Codex
FSAI Food Safety Authority of Ireland
FSMP Food for special medical purposes
FTIR Fourier-transforming infrared
GCP Good clinical practices
GLP Good laboratory practices
GMP Good manufacturing practices
HACCP Hazard Analysis Critical Control Point
HPLC high-performance liquid chromatography
ICP-AES inductively coupled plasma atomic emission spectroscopy
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ISE ion selective electrode
JECFA Joint FAO/WHO Expert Committee on Food Additives
MS mass spectroscopy
NLT Not less than
NMT Not more than
PARNUTS Foods for Particular Nutritional Uses
SCF Scientiﬁc Committee on Food
t1/2 half-life
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